We're a team of engineers, designers, and product builders that were brought in to help fix HealthCare.gov in the winter of 2013. Since then, we've been working with the government to improve the services HealthCare.gov provides. The new application process that we designed and built is now used by millions each year to sign up for health insurance, and has helped America reach its lowest uninsured rate ever. With our experience repairing complex systems at HealthCare.gov we've seen how building with high expectations, clear design, and scalable infrastructure can create dramatic benefits. We've been the firefighters — now we're the architects. We're proud of what we've been able to do, but our work is far from done. We've since begun work with both the Department of Veterans Affairs and Medicare. We are focused on modernizing the VA's appeals processing systems — Veterans currently wait, on average, five years to receive a resolution. For Medicare, we are designing and building the architecture for Medicare's historic transition towards value-based care. We've started Nava as a public benefit corporation to radically improve how our government serves its people. We believe that the services our government provides should be clear and reliable. We're here for the people that have no seat at the table – design for them, make decisions for them. We are their advocate and an active and responsible steward of that power. Reimagining critical government services

Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The Company's proprietary ARC-sparX platform separates the tumor-recognition and tumor-killing functions of conventional CAR-T cell therapies: (1) sparX (soluble protein antigen-receptor X-linkers) proteins recognize and bind specific antigens on diseased cells and flag those cells for destruction; and (2) ARC-T (Antigen Receptor Complex-T) cells bind the sparX proteins and kill the flagged cells. Arcellx has developed a collection of sparX proteins that bind different cell surface antigens. Administration of alternate sparX proteins can redirect ARC-T cells to different disease antigens to potentially address relapsed and refractory disease due to tumor heterogeneity or antigen escape. Additionally, ARC-T cell activity can be curbed as needed by controlling the dose and frequency of sparX administration.